Rethinking Invasive Mediastinal Staging in the Era of Neoadjuvant Immune-Checkpoint Inhibitors.

Area of Science:

• Oncology
• Thoracic Surgery
• Immunotherapy

Background:

• Historically, mediastinal lymph node evaluation determined surgical eligibility for non-small cell lung cancer (NSCLC).
• This assessment guided decisions between upfront surgery and definitive chemoradiotherapy.
• Non-metastatic NSCLC management focused on identifying patients for surgical resection.

Purpose of the Study:

• To re-examine the role of mediastinal assessment in non-metastatic NSCLC following the integration of immune checkpoint inhibitors (ICIs).
• To explore how neoadjuvant ICI therapy impacts traditional staging and clinical decision-making.
• To discuss implications for future clinical trial design in the immunotherapy era.

Main Methods:

• Synthesis of emerging evidence on neoadjuvant ICI therapy in NSCLC.
• Review of evolving clinical concepts regarding mediastinal assessment.
• Analysis of the impact of ICIs on pathologic response and survival in N2 disease.

Main Results:

• Neoadjuvant ICI therapy significantly improves pathologic response and survival in patients with N2 disease.
• The prognostic weight of mediastinal nodal involvement is being reshaped by ICI efficacy.
• Mediastinal assessment may shift from primarily excluding patients from surgery to risk stratification and response evaluation.

Conclusions:

• Immune checkpoint inhibitors are transforming the management paradigm for non-metastatic NSCLC.
• Mediastinal assessment's role is evolving beyond surgical exclusion to include risk stratification and response assessment.
• These changes necessitate re-evaluation of staging practices and clinical decision-making in the immunotherapy era for NSCLC.